Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Sands, Bruce E.
5683  Ergebnisse:
Online X
Personensuche X
?
1

989 EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEE..:

Vermeire, Séverine ; Peyrin-Biroulet, Laurent ; Danese, Silvio...
Gastroenterology.  166 (2024)  5 - p. S-241 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for..:

Hanauer, Stephen B. ; Sands, Bruce E. ; Schreiber, Stefan...
Gastroenterology.  , 2024
Link: https://doi.org/10.1053/..
 
?
3

Basket, Umbrella, and Platform Trials: The Potential for Ma..:

Honap, Sailish ; Sands, Bruce E. ; Jairath, Vipul...
Gastroenterology.  , 2024
Link: https://doi.org/10.1053/..
 
?
4

Combination Therapy With Guselkumab and Golimumab in Patien..:

Shao, Jie ; Vetter, Marion ; Vermeulen, An...
Clinical Pharmacology & Therapeutics.  115 (2024)  6 - p. 1418-1427 , 2024
Link: https://doi.org/10.1002/..
 
?
5

759 THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE TH..:

Rubin, David T. ; Allegretti, Jessica R. ; Panés, Julián...
Gastroenterology.  166 (2024)  5 - p. S-180 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Ozanimod in Patients With Moderate to Severe Ulcerative Col..:

Sands, Bruce E. ; D'Haens, Geert ; Panaccione, Remo...
Clinical Gastroenterology and Hepatology.  , 2024
Link: https://doi.org/10.1016/..
 
?
7

Tu1751 DISTINCT PERTURBANCES IN METABOLIC PATHWAYS ASSOCIAT..:

Bourgonje, Arno R. ; Ibing, Susanne ; Argmann, Carmen A....
Gastroenterology.  166 (2024)  5 - p. S-1405-S-1406 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Tu1770 DISEASE DURATION IMPACTS INTESTINAL GENE EXPRESSION ..:

Ibing, Susanne ; Tastad, Christopher ; Renard, Bernhard Y....
Gastroenterology.  166 (2024)  5 - p. S-1414 , 2024
Link: https://doi.org/10.1016/..
 
?
9

Mo1736 DIETARY INTERVENTIONS AND SUPPLEMENTATION IN PATIENT..:

Gold, Stephanie L. ; Levinson, Carrie ; Colombel, Jean Frederic...
Gastroenterology.  166 (2024)  5 - p. S-1090 , 2024
Link: https://doi.org/10.1016/..
 
?
10

Differences between the 2016 and 2022 FDA guidance – implic..:

Hanzel, Jurij ; Ma, Christopher ; Peyrin-Biroulet, Laurent...
Crohn's & Colitis 360.  , 2024
Link: https://doi.org/10.1093/..
 
?
11

Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE C..:

Sandborn, William J. ; Sands, Bruce E. ; Hanauer, Stephen B....
Gastroenterology.  166 (2024)  5 - p. S-810 , 2024
Link: https://doi.org/10.1016/..
 
?
12

Tu1752 MILD CROHN'S DISEASE IS CHARACTERIZED BY A UNIQUE SE..:

Bourgonje, Arno R. ; Ibing, Susanne ; Argmann, Carmen A....
Gastroenterology.  166 (2024)  5 - p. S-1406 , 2024
Link: https://doi.org/10.1016/..
 
?
13

Mo1831 SYSTEMATIC REVIEW WITH META-ANALYSIS: SAFETY AND EFF..:

Osman, Ali ; Anderson, Scott R. ; Zamani, Mohammad...
Gastroenterology.  166 (2024)  5 - p. S-1133-S-1134 , 2024
Link: https://doi.org/10.1016/..
 
?
14

Dietary Interventions and Supplementation in Patients With ..:

Gold, Stephanie ; Levinson, Carrie ; Colombel, Jean-Frederic...
Inflammatory Bowel Diseases.  , 2024
Link: https://doi.org/10.1093/..
 
?
15

Su1762 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE T..:

Hanauer, Stephen B. ; Colombel, Jean Frederic ; Sandborn, William J....
Gastroenterology.  166 (2024)  5 - p. S-802 , 2024
Link: https://doi.org/10.1016/..
 
1-15